Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM romiplostim for chemotherapy-induced thrombocytopenia
2018-001006-28Phase 3Active
- Sponsor
- Amgen
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Romiplostim + chemotherapy with Placebo + chemotherapy (2 arms). Started Sep 2019; status: active.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2018-001006-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001006-28.